How to Buy Summit Therapeutics Stock
Summit Therapeutics Inc
Summit Therapeutics Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America.
Summit Therapeutics stock last closed at $22.99, up 1.68% from the previous day, and has increased 204.5% in one year. It has overperformed other stocks in the Biotechnology industry by 2.75 percentage points. Summit Therapeutics stock is currently +191.38% from its 52-week low of $7.89, and -37.71% from its 52-week high of $36.91.
There are currently 742.67M SMMT shares outstanding. The market capitalization of SMMT is $17.07B. In the past 24 hours, 2.99M SMMT shares were traded.
How to Buy Summit Therapeutics Stock
Wondering how to invest in Summit Therapeutics stock? Here's how.
- Decide where to buy Summit Therapeutics stock: You need to choose an online brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you choose where to buy Summit Therapeutics stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Fund your brokerage account: Select your method of payment and add your details.
- Evaluate Summit Therapeutics stock: The Summit Therapeutics ticker symbol is SMMT. Is Summit Therapeutics stock a good investment? Should you buy shares of SMMT? How do SMMT's underlying business fundamentals look? Do top analysts think Summit Therapeutics is a good buy? Why has SMMT's stock price moved recently? (Hint: Our stock market research website can help you figure out if SMMT is a good stock to buy).
- Place your SMMT buy order: Decide if you will purchase SMMT shares at the current market price or use a limit order to buy SMMT stock at a specific price.
- Get the latest news on your SMMT investment: Create a watchlist to watch your investment in Summit Therapeutics shares.
Step 1: Decide where to buy Summit Therapeutics stock
You will need a brokerage account to access the NASDAQ market and buy SMMT shares.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Technology to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro boasts a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've picked the right brokerage, it's time to fill out some personal details so you can invest in SMMT stock today.
How to Start a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to start your new trading account.
- Submit your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've filled out your info on stock market apps, you can securely and quickly fund your account:
Watch the video below if you need help transferring money into your new brokerage account.
Step 4: Evaluate Summit Therapeutics stock
After you have chosen the best place to buy Summit Therapeutics stock, it's absolutely critical to research their stock prior to investing, so you truly understand the risk and opportunity.
Summit Therapeutics Metrics
Summit Therapeutics Due Diligence Checks
WallStreetZen was designed to help part-time investors do better fundamental analysis quickly.
You can see all of the due diligence checks on SMMT's stock page.
What is the fair value of SMMT stock?
Investors use many financial metrics, analyses, models, and charts to gauge SMMT's fair value.
Using relative valuations metrics:
- SMMT could be overvalued based on its P/B ratio of 49.59x, relative to Biotechnology industry P/B ratio of 4.53x
You can access more valuation analysis on SMMT's stock here.
SMMT Financial Health
Passed Financial Due Diligence Checks:
- SMMT has a low debt to equity ratio of 0.12.
- SMMT has cash burn of 173697000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the SMMT balance sheet.
- There are more short-term assets than short-term liabilities on the SMMT balance sheet.
- Total SMMT debt is lower than 5 years ago, relative to shareholder equity.
Failed Financial Due Diligence Checks:
- SMMT has $361.63M in cash and short term investments. This is not enough to cover its annual cash burn of $173.70M.
Do analysts think it's a good time to buy SMMT stock
Out of 8 Wall Street analysts who research SMMT, the consensus analyst rating on SMMT is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Most Recent SMMT Analyst Forecasts
Kelly Shi, a bottom 6% analyst from Jefferies maintains SMMT with a strong buy rating and raises their SMMT price target from $31.00 to $44.00, on Apr 25, 2025.
Yigal Nochomovitz, a top 16% analyst from Citigroup upgrades SMMT to a strong buy rating and raises their SMMT price target from $23.00 to $35.00, on Mar 26, 2025.
Citigroup's Yigal Nochomovitz upgraded their rating on Summit Therapeutics (NASDAQ: SMMT) from Hold to Strong Buy on 2025/03/26. The analyst also raised their price target by 52.2% from $23 to $35.
With a 70% chance of producing a favorable year-end readout, Citigroup has a "strong conviction" in the HARMONi-2 trial, Nochomovitz told readers.
If Summit Therapeutics' ivonescimab is confirmed to effectively increase the survival rate in non-small cell lung cancer patients, it would be a game-changer in the field of immunotherapy, the analyst said.
Footnotes
HARMONi-2 is a Phase III clinical trial that compares the efficacy of ivonescimab with pembrolizumab as a first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer.
Ivonescimab, also known as AK112, is a humanized bispecific monoclonal antibody designed to target two key proteins: PD-1 (programmed cell death protein 1) and VEGF (vascular endothelial growth factor). By blocking these proteins, ivonescimab aims to prevent tumor growth and angiogenesis.
Pembrolizumab, marketed as Keytruda, is a humanized monoclonal antibody used in cancer immunotherapy. It works by targeting the PD-1 (programmed death receptor-1) protein in immune cells, which cancer cells often exploit to evade detection by the immune system.
Cory Kasimov, a top 22% analyst from Evercore ISI Group initiates coverage on SMMT with a buy rating and announces their SMMT price target of $30.00, on Mar 12, 2025.
You can dig deeper into what analysts are saying on the Summit Therapeutics stock forecast page.
SMMT Trading Indicators
Is SMMT Growing Revenue?
Last year, SMMT revenue was $0.00. Over the last 4 year, SMMT's revenue has gone up by -100% per year. This was slower than the Biotechnology industry average of 42.32%.
Learn more about SMMT's earnings and revenue performance here.
What are SMMT executives and large shareholders up to?
In the last year, insiders at SMMT have bought more shares than they have sold.
Robert W. Duggan, Co-Chief Executive Officer of SMMT, was the latest SMMT insider to buy. They bought $196,798.80 worth of SMMT shares on May 30, 2025.
Research more about who owns SMMT shares here.
Can I rely on SMMT as an income stream?
No, Summit Therapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Place your SMMT buy order
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly the easiest way to buy. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a particular dollar amount, place a limit order.
Click the Open button and eToro will place your order.
If you want additional help investing in stocks on eToro, click the how to video below:
Step 6: Get the latest news on your SMMT investment
Now that you own some SMMT stock, you'll want to keep up with your investment.
Start a watchlist to see the latest developments about your SMMT stock.
SMMT Feed
How to Buy Stock in Summit Therapeutics
To reiterate, here are the 6 steps to buy stock in Summit Therapeutics:
- Decide where to buy Summit Therapeutics stock
- Create your brokerage account
- Fund your brokerage account
- Evaluate Summit Therapeutics stock
- Place your SMMT buy order
- Get the latest news on your SMMT investment
If you require a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to track your new investment in Summit Therapeutics, create a watchlist on WallStreetZen today.
Other Stock Buying Guides You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.